Visceral leishmaniasis associated with human immunodeficiency virus infection (Q43826423)

27 November 2017

1 reference

title

Visceral leishmaniasis associated with human immunodeficiency virus infection (English)

1 reference

27 November 2017

main subject

visceral leishmaniasis

1 reference

Pintado V

1

1 reference

27 November 2017

López-Vélez R

series ordinal

2

1 reference

27 November 2017

publication date

1 August 2001

1 reference

Infectious Diseases and Clinical Microbiology

27 November 2017

published in

1 reference

27 November 2017

volume

19

1 reference

27 November 2017

issue

7

1 reference

27 November 2017

page(s)

353-357

1 reference

HIV-associated visceral leishmaniasis

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Visceral leishmaniasis in patients infected with the human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART)

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

AIDS and Leishmania infantum. New approaches for a new epidemiological problem

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Visceral leishmaniasis in patients infected with human immunodeficiency virus. Co-operative Group for the Study of Leishmaniasis in AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV).

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

HIV-Leishmania co-infections in Italy: serological data as an indication of the sequence of acquisition of the two infections

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Visceral leishmaniasis and HIV-1 co-infection in southern France

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Comparison of PCR with direct examination of bone marrow aspiration, myeloculture, and serology for diagnosis of visceral Leishmaniasis in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome)

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Efficacy of liposomal amphotericin B in the treatment and secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Relapsing visceral leishmaniasis in HIV-infected patients undergoing successful protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

Prospective Evaluation and Follow-Up of European Patients with Visceral Leishmaniasis and HIV-1 Coinfection in the Era of Highly Active Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0213-005X%2801%2972665-1

7 January 2021

10.1016/S0213-005X(01)72665-1

Identifiers

DOI

1 reference

27 November 2017

1 reference